Telehealth providers including Hims & Hers and Noom announced intentions to offer peptides if federal rules ease, addressing a market estimated by analysts at $2 billion to $3 billion.

From the articleTrump administration advances plan for peptide drugs favored by RFK Jr.Also in US FDA takes step to change peptide compounding policy | Reuters, US FDA moves to ease rules on compounding some peptides | Межа, Trump administration advances plan for peptide drugs favored by RFK Jr.